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Summary
Background International consensus recognises four medulloblastoma molecular subgroups: WNT (MBWNT), SHH 
(MBSHH), group 3 (MBGrp3), and group 4 (MBGrp4), each defined by their characteristic genome-wide transcriptomic and 
DNA methylomic profiles. These subgroups have distinct clinicopathological and molecular features, and underpin 
current disease subclassification and initial subgroup-directed therapies that are underway in clinical trials. However, 
substantial biological heterogeneity and differences in survival are apparent within each subgroup, which remain to 
be resolved. We aimed to investigate whether additional molecular subgroups exist within childhood medulloblastoma 
and whether these could be used to improve disease subclassification and prognosis predictions.
Methods In this retrospective cohort study, we assessed 428 primary medulloblastoma samples collected from UK 
Children’s Cancer and Leukaemia Group (CCLG) treatment centres (UK), collaborating European institutions, and 
the UKCCSG-SIOP-PNET3 European clinical trial. An independent validation cohort (n=276) of archival tumour 
samples was also analysed. We analysed samples from patients with childhood medulloblastoma who were aged 
0–16 years at diagnosis, and had central review of pathology and comprehensive clinical data. We did comprehensive 
molecular profiling, including DNA methylation microarray analysis, and did unsupervised class discovery of test and 
validation cohorts to identify consensus primary molecular subgroups and characterise their clinical and biological 
significance. We modelled survival of patients aged 3–16 years in patients (n=215) who had craniospinal irradiation 
and had been treated with a curative intent.
Findings Seven robust and reproducible primary molecular subgroups of childhood medulloblastoma were identified. 
MBWNT remained unchanged and each remaining consensus subgroup was split in two. MBSHH was split into age-
dependent subgroups corresponding to infant (<4·3 years; MBSHH-Infant; n=65) and childhood patients (≥4·3 years; 
MBSHH-Child; n=38). MBGrp3 and MBGrp4 were each split into high-risk (MBGrp3-HR [n=65] and MBGrp4-HR [n=85]) and low-risk 
(MBGrp3-LR [n=50] and MBGrp4-LR [n=73]) subgroups. These biological subgroups were validated in the independent cohort. 
We identified features of the seven subgroups that were predictive of outcome. Cross-validated subgroup-dependent 
survival models, incorporating these novel subgroups along with secondary clinicopathological and molecular features 
and established disease risk-factors, outperformed existing disease risk-stratification schemes. These subgroup-
dependent models stratified patients into four clinical risk groups for 5-year progression-free survival: favourable risk 
(54 [25%] of 215 patients; 91% survival [95% CI 82–100]); standard risk (50 [23%] patients; 81% survival [70–94]); high-
risk (82 [38%] patients; 42% survival [31–56]); and very high-risk (29 [13%] patients; 28% survival [14–56]).
Interpretation The discovery of seven novel, clinically significant subgroups improves disease risk-stratification and 
could inform treatment decisions. These data provide a new foundation for future research and clinical investigations.
Funding Cancer Research UK, The Tom Grahame Trust, Star for Harris, Action Medical Research, SPARKS, The JGW 
Patterson Foundation, The INSTINCT network (co-funded by The Brain Tumour Charity, Great Ormond Street 
Children’s Charity, and Children with Cancer UK).
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Introduction
The discovery of molecular disease subgroups represents 
the most fundamental advance in our understanding of 
medulloblastoma, the most common malignant brain 
tumour of childhood. Current international consensus 
recognises four subgroups of medulloblastoma: WNT 
(MBWNT), SHH (MBSHH), group 3 (MBGrp3) and group 4 
(MBGrp4).1 Each subgroup is defined empirically by 
genome-wide transcriptomic2–6 and DNA methylation 
patterns7,8 and characterised by distinct clinicopathological 
and molecular features.9–12 MBWNT and MBSHH are 
synonymous with WNT and SHH activating mutations.12 
By contrast, MBGrp3 and MBGrp4 have few mutations, but 
have multiple DNA copy number alterations.9–12
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Subgrouping is integral to the 2016 WHO 
medulloblastoma classification,13 and is used to direct 
treatment strategies aimed at improving cure rates (5-year 
survival across all four subgroups is 65–70%), and 
reducing long-term intellectual and neuroendocrine 
impairments associated with existing multimodality 
therapies. Patients with childhood MBWNT consistently 
show a favourable prognosis (>90% survival14,15) and 
reduced intensity risk-adapted therapies are being studied 
in these patients in international clinical trials,16 whereas 
SHH pathway inhibitors show promise in MBSHH disease 
in early-phase trials,17 although treatment of infants 
(younger than 3 years at diagnosis) and young children 
with these inhibitors should be approached with caution, 
because of the risk of premature fusion of growth-plates.18
Substantial biological heterogeneity is evident within 
each non-MBWNT subgroup; for instance, TP53 mutations 
are associated with a poor outcome in MBSHH.13,19 High-
risk clinical factors (metastatic disease [M+]; large-cell, 
anaplastic [LCA] pathology; incomplete surgical resection 
[R+]; and MYC/MYCN amplification), which are 
currently used to stratify risk in medulloblastoma in 
children aged 3 years or older, were derived from cohort-
wide investigations before discovery of the consensus 
subgroups, and thus did not consider their effect.15,16,20,21
Studies that defined the four-subgroup consensus used 
modestly sized cohorts (typically fewer than 
200 patients).2–6 In this Article, we describe comprehensive 
molecular profiling of clinically annotated discovery and 
validation cohorts totalling more than 700 tumours. 
We report the discovery and characterisation of seven 
stable and reproducible primary subgroups of childhood 
medulloblastoma (in patients younger than 16 years at 
diagnosis), which subdivide each of the classic consensus 
non-MBWNT subgroups (MBSHH, MBGrp3, and MBGrp4) into 
two clinically significant groups with distinct 
clinicomolecular features and survival outcomes. 
Methods
Study design and participants
In this retrospective cohort study, we assessed 428 centrally 
reviewed, clinically annotated primary medulloblastomas 
from patients aged 0–16 years at diagnosis, collected from 
UK Children’s Cancer and Leukaemia Group (CCLG) 
treatment centres (UK; 366 [86%]), collaborating European 
institutions in Budapest (Hungary; 20 [5%]) and Warsaw 
(Poland; 15 [4%]), and samples from the European 
UKCCSG-SIOP-PNET3 clinical trial (27 [6%]). As is typical 
for medulloblastoma, we regarded patients younger than 
3 years at diagnosis as infants. 108 (26%) of 408 patient 
samples used were collected in 2010–14, 192 (47%) in 
2000–10, 85 (21%) in 1990–2000, and the remaining 
23 (6%) were collected before 1990 (18 were from the 
1980s, four from the 1970s, and one was from 1968). Year 
of diagnosis was unavailable for 20 samples.
Tumour samples were provided by the UK CCLG as 
part of CCLG-approved biological study BS-2007–04; 
informed, written consent was obtained from parents of 
all patients because all assessed patients were younger 
than 16 years. Tumour investigations were done with 
Research in context
Evidence before this study
The international consensus definition of medulloblastoma, 
published in 2012, recognises four primary molecular 
subgroups with distinct clinicopathological features: WNT 
(MBWNT), SHH (MBSHH), group 3 (MBGrp3), and group 4 (MBGrp4). 
Several studies established characteristic genome-wide 
transcriptomic and DNA methylomic profiles, using 
unsupervised class discovery techniques, which defined the 
consensus subgroups. These subgroups, described in the 
2016 WHO classification of brain tumours, underpin current 
disease subclassification, research studies, and clinical trials. 
Profiling and class discovery studies published to date in 
medulloblastoma are based on cohorts typically with sample 
sizes less than 200 patients and, even within the consensus 
subgroups, significant heterogeneity of clinical and 
molecular features remains and many relationships to 
disease outcome are unresolved. Evidence from the 
component studies and reviews undertaken in the 
international consensus definition and the 2016 WHO 
classification, alongside our own reviews of the current 
literature, formed the foundation for the present study; 
no systematic reviews were carried out.
Added value of this study
We defined and characterised seven robust, reproducible, clinically 
significant, primary molecular subgroups within childhood 
medulloblastoma (in children aged up to 16 years at diagnosis), 
each with distinct clinicomolecular features. We propose a 
cross-validated, subgroup-dependent survival model that 
incorporates these novel subgroups, alongside established disease 
features and risk-factors and outperforms the disease 
risk-stratification schemes in current clinical use. Redistribution of 
disease risk using this scheme identifies substantial proportions of 
favourable-risk non-infant patients (>90% 5-year survival in 11% 
of patients) outside the MBWNT subgroup (equivalent to 
approximately 70 patients per year in the European Union [EU]) 
who would be suitable for consideration of reduced intensity of 
therapy, and very-high-risk non-infant patients (<40% survival, 
13% of patients, about 80 EU patients per year) for whom new 
treatment strategies should be prioritised.
Implications of all the available evidence
These data provide a step-change in our understanding and 
characterisation of molecular subgroups within medulloblastoma, 
with potential application to future disease subclassification, 
risk-stratification, and subgroup-dependent translational research.
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approval from Newcastle North Tyneside Research Ethics 
Committee (study reference 07/Q0905/71); all tumour 
material was collected in accordance with this approval. 
We used 276 medulloblastomas (GSE54880) from a 
published tumour archive,8 comprising patients aged 
from 0–18 years at diagnosis, as an independent validation 
cohort. 18 post-mortem cerebellar samples were collected 
from the Newcastle Brain Tissue Resource and used as 
controls in some analyses; all samples were collected with 
written, informed consent.
Procedures
We tested medulloblastoma samples with the Illumina 
HumanMethylation450K DNA methylation array (Illumina, 
San Diego, CA, USA). The Gene Expression Omnibus 
accession number for 450K DNA methylation array profiles 
we used for the determination of human medulloblastoma 
molecular subgroup status is GSE93646.
To identify methylation-dependent subgroups, we did 
unsupervised class discovery by NMF-metagene and 
k-means clustering, testing all combinations of 
3–10 metagenes and clusters for reproducibility using 
bootstrapped resampling methods (250 iterations) as 
described previously.7 This analysis identified metagenes 
(a single score that reflects the methylation status of 
several CpG loci) representing the main biological effects 
present in the genome-wide dataset. We assessed cluster 
stability using the cophenetic index, a shorthand measure 
of the robustness of sample clustering as determined by 
consensus non-negative matrix factorisation (appendix 
p 3). We visualised clusters with t-SNE.22 We assigned 
samples classified with less than 80% confidence (by 
resampling procedures) as non-classifiable (NC; 
appendix pp 2–3).
We projected metagenes derived from our discovery 
cohort onto the validation cohort. Additionally, we 
combined the discovery and validation cohorts to do 
equivalent consensus clustering.
We assessed established medulloblastoma clinical, 
pathological, and molecular features as described 
previously.7 Briefly, we defined histopathological variants 
according to the WHO 2016 guidelines.13 We assigned 
metastatic status (M+) based on Chang’s criteria 
(appendix p 3). Tumours were designated as R+ if their 
residuum after surgical excision exceeded 1·5 cm². 
Pathology was centrally reviewed by three experienced 
neuropathologists for 380 (89%) of 428 samples, and 
clinical data were collated from contributing centres and 
reviewed centrally (appendix p 3). We assessed MYC and 
MYCN status by fluorescence in situ hybridisation or 
copy-number estimates from methylation array. 
We assessed TP53, CTNNB1, and TERT mutation status 
by Sanger sequencing. We identified subgroup-specific 
differentially methylated CpG loci or methylated regions 
(DMRs) using limma or DMRcate23,24 (appendix p 3). 
RNA-seq expression data were generated for discovery 
cohort samples for which mRNA of sufficient quantity 
and quality was available. We identified subgroup-
specific differentially expressed genes using DESeq2,25 
and these genes were included in ontology enrichment 
analyses (appendix p 4). We identified GFI1 mutations 
from RNA-seq data (appendix p 4).
MBSHH mutation data were obtained from a previous 
study.26 Although 450K methylation data for MBSHH 
subgroup assignment were not available for this sample 
cohort, the tightly defined age cutoff that we defined 
between the molecularly determined MBSHH-Infant and 
MBSHH-Child subgroups enabled us to infer subgroups for 
this sequencing cohort (appendix p 4).26 We tested 
recurrent MBSHH mutations (TP53, SUFU, PTCH1, SMO, 
and TERT) and gene amplifications (MYCN and GLI2) 
identified by whole genome sequencing, for association 
with the age-defined MBSHH-Child or MBSHH-Infant subgroups 
using Fisher’s exact test (appendix p 4).
Statistical analysis
We did survival analyses (overall survival and progression-
free survival) on samples from patients aged 3–16 years 
within our discovery cohort, who received maximal 
surgical resection and craniospinal irradiation with 
curative intent. Overall survival was defined as the time 
from date of surgery to death or date of last follow-up and 
progression-free survival as the time from date of surgery 
to first event (progression or relapse) or date of last 
follow-up. Patients with follow-up time that exceeded 
10 years were right-censored at 10 years.
The tightly defined age cutoff between the molecularly 
determined MBSHH-Infant and MBSHH-Child subgroups enabled 
us to assess an expanded survival cohort of MBSHH-Child 
disease (n=55), including additional samples with 
insufficient DNA for methylation array analysis, classified 
as MBSHH-Child on the basis of their age (appendix p 4). In this 
group, we assessed the prognostic potential of currently 
used clinical and molecular risk markers (M+ disease, R+ 
disease, LCA pathology, sex, MYCN amplification, TERT 
mutation, and TP53 mutation [appendix pp 4–5]). Patients 
in the MBSHH-Infant subgroup were typically younger than 
3 years at diagnosis and were, therefore, treated on infant 
protocols. Treatment in this group of patients is 
heterogeneous, and is focused on omitting or delaying 
radiotherapy to reduce treatment-associated morbidities 
as far as possible. As a consequence, we report only overall 
survival in this group.
We created univariate and cross-validated multivariate 
Cox models based on subgroups, established risk factors, 
and cytogenetic changes. Prognostic markers in the 
multivariate analysis were identified by performing 
100 rounds of 10-fold cross-validation, evaluating the 
performance of markers by measuring area under the 
curve (AUC) at 5 years for progression-free survival in the 
left out fold, and calculating the overall mean AUC over all 
rounds (appendix p 5). We added variables conferring an 
increase in AUC, as measured by time-dependent receiver 
operating characteristic curves at 5 years, to the model. 
See Online for appendix
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Because MBGrp3 and MBGrp4 shared a metagene (V1), which 
defined a low-risk outcome and implied shared biology, 
we considered MBGrp3/4 as a single entity, and MBGrp3 and 
MBGrp4 separately for creation of survival models. Ixdition 
to currently understood clinical and molecular risk 
markers in these groups (M+ disease, R+ disease, LCA 
pathology, gender, MYC/MYCN amplification, and i17q 
[isochromosome 17q]), we additionally tested for recurrent 
cytogenetic changes, MBGrp3 membership, and 
membership of the high-risk methylomic group composed 
of members from both MBGrp3 and MBGrp4, defined by 
metagene V1 (appendix pp 5–6). We categorised identified 
independent prognostic markers into risk-stratification 
schemes (favourable-risk, >90% survival; standard-risk, 
>75–90% survival; high-risk, 40–75% survival; very high-
risk, <40% survival) and survival-dependent ROC analysis 
of progression-free survival at 5 years, to assess 
performance27 by comparison with previously reported 
classification schemes (appendix pp 5–6).16,28
We constructed Kaplan-Meier curves and compared 
patient groups with log-rank tests. For Kaplan-Meier 
comparison of two groups, we calculated hazard ratios 
(HRs) for the 0–5 year survival interval and 95% CIs 
from the Wald statistic. We tested the proportionality 
assumption for Cox modelling using scaled Schoenfeld 
residuals. Missing data were assumed to be missing 
completely at random and affected samples were 
removed from multivariate analyses. We implemented 
array processing, normalisation, quality-control checks, 
and copy-number estimation, relative to a panel of 
18 normal cerebella with the R packages minfi29 and 
conumee (appendix p 2).
The significance threshold was set at p<0·05 for all 
statistical tests in this study, unless otherwise stated. 
Significance of association was assessed using Fisher’s 
exact and chi-squared tests with Yates’ continuity 
correction. We identified subgroup-specific age-differences 
between the non-MBWNT or non-MBSHH medulloblastoma 
subgroups using ANOVA (appendix p 4). Statistical or 
bioinformatics analyses were done using R (version 3.2.3).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all of the data and had the final responsibility to 
submit for publication.
Results
Clinicopathological and molecular diagnostic 
characteristics of 428 patients younger than 16 years who 
had primary childhood medulloblastoma (discovery 
cohort) are shown in table 1. Consensus analysis 
identified two equally robust cluster solutions (cophenetic 
index 0·998 [ four metagenes] and 0·997 [six metagenes]; 
appendix p 10). The first cluster solution (four metagenes, 
four clusters) recapitulated the established four-subgroup 
consensus,1 whereas the second (six metagenes, seven 
clusters) revealed further clusters within the established 
subgroups (figure 1A, appendix pp 10–11).
Discovery cohort 
(n=428)
Validation cohort 
(n=276)
MBSHH-Child survival 
cohort (n=55)
MBGrp3/4 survival 
cohort (n=175)
Sex
Male 278 (65%) 174 (63%) 32 (58%) 124 (71%)
Female 150 (35%) 102 (37%) 23 (42%) 51 (29%)
Male:female 
ratio
1·9:1 1·7:1 1·4:1 2·4:1
Age at diagnosis (years)
Median (range) 6·34 (0·24–15·97) 7·50 (0·0–18·0) 10·86 (3·5–15·54) 7·33 (3·4–15·97)
<3 101 (24%) 30 (11%) 0 0
≥3 327 (76%) 244 (89%) 55 (100%) 175 (100%)
Pathology variant
Classic 276 (70%) NA 23 (44%) 131 (83%)
DN/MBEN 58 (15%) NA 15 (29%) 7 (5%)
LCA 60 (15%) NA 14 (27%) 19 (12%)
MB-NOS 34 NA 3 18
Metastatic stage
M– 285 (73%) NA 47 (85%) 124 (73%)
M+ 104 (27%) NA 8 (15%) 47 (27%)
Resection
Sub-total 
resection (R+)
98 (26%) NA 9 (16%) 51 (29%)
Gross total 
resection (R–)
285 (74%) NA 46 (84%) 123 (71%)
Treatment
RTX alone 28 (8%) NA 16 (33%) 16 (9%)
RTX and CTX 314 (92%) NA 32 (67%) 157 (91%)
Follow-up time 
(years)
4·91 (0·2–25·7) NA 6·52 (0·5–16·8) 4·58 (0·4–25·7)
CTNNB1 mutation
Mutant 24 (7%) NA NA 0
Wild-type 297 (93%) NA NA 144 (100%)
Chromosome 6
Loss 30 (8%) 28 (10%) NA 0
Normal 361 (92%) 248 (90%) NA 158 (100%)
Chromosome 17
i17q 111 (28%) 87 (32%) NA 72 (46%)
No i17q 280 (72%) 189 (68%) NA 86 (54%)
MYC amplification
Positive 22 (5%) 12 (4%) NA 8 (5%)
Negative 404 (95%) 264 (96%) NA 165 (95%)
MYCN amplification
Positive 29 (7%) 17 (6%) NA 11 (6%)
Negative 397 (93%) 259 (94%) NA 162 (94%)
TP53 mutation
Positive 18 (7%) NA 13 (27%) 1 (1%)
Negative 238 (93%) NA 35 (73%) 89 (99%)
TERT mutation
Positive 16 (4%) NA 18 (35%) 1 (1%)
Negative 357 (96%) NA 34 (65%) 150 (99%)
(Table 1 continues on next page)
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MBWNT tumours formed a single subgroup (n=33) 
characterised by CTNNB1 mutations, loss of 
chromosome 6, and an expected favourable prognosis 
(5-year overall survival: 93% [95% CI 82–100]; figure 1B). 
Our newly detected metagenes split each remaining 
consensus subgroup (MBSHH, MBGrp3, and MBGrp4) in two. 
MBSHH was split into age-dependent subgroups 
corresponding to infant (<4·3 years; MBSHH-Infant; n=65) 
and childhood patients (≥4·3 years; MBSHH-Child; n=38) by 
the respective absence or presence of metagene V4. Both 
have intermediate prognoses (5-year overall survival 
MBSHH-Child: 58% [95% CI 41–82]; MBSHH-Infant: 62% [50–77]; 
figure 1B). MBGrp3 and MBGrp4 are each split into high-risk 
(MBGrp3-HR [n=65] and MBGrp4-HR [n=85]) and low-risk 
(MBGrp3-LR [n=50] and MBGrp4-LR [n=73]) subgroups by 
common metagene V1 (figure 1A). 5-year overall survival 
was 37% [95% CI 25–53] in the MBGrp3-HR subgroup, 
69% [55–87] in the MBGrp3-LR subgroup, 69% [58–83] in the 
MBGrp4-HR subgroup, and 80% [70–92] in the MBGrp4-LR 
subgroup (figure 1B). The subdivision of MBGrp3 and 
MBGrp4 distinguishes patients with a superior stratification 
(5-year overall survival AUC 0·649 [MBGrp3/4 combined 
with low-risk or high-risk subdivision]) compared with 
the current consensus MBGrp3 and MBGrp4 subgroups 
(AUC 0·610). Moreover, in the patients aged 3–16 years at 
diagnosis and receiving craniospinal irradiation, the 
high-risk or low-risk subdivision of MBGrp3/4 stratifies this 
group into standard (MBGrp3-LR 81% [95% CI 60–100%]; 
MBGrp4-LR 81% [71–93%]) and high-risk (MBGrp3-HR 35% 
[23–55%]; MBGrp4-HR 47% [34–66%]) 5-year progression-
free survival outcomes, by contrast with the current 
consensus MBGrp3/4 designations, which show 
intermediate outcomes (figure 1C, 1D).
Clinicopathological and biological features were non-
randomly distributed in all seven subgroups (figure 1A, 
appendix pp 12–15). Patients in the MBSHH-Infant subgroup 
had significantly enriched desmoplastic or nodular 
pathology compared with all other subgroups (p<0·0001), 
and TP53 mutation (p<0·0001) and MYCN amplifications 
(p<0·0001) were significantly more frequent in MBSHH-Child 
than in all other subgroups. Patients in the MBGrp3-HR 
subgroup significantly more frequently had LCA 
pathology (p<0·0001) and MYC amplification (p<0·0001), 
than all other subgroups. Although patients in the 
MBGrp3-HR and MBGrp4-HR subgroups had similar 10-year 
overall survival (22% [95% CI 10–46] vs 36% [22–59]; 
figure 1B), patients in the MBGrp4-HR subgroup died later of 
their disease (ten [36%] of 28 deaths in the MBGrp4-HR 
subgroup occurred more than 5 years after diagnosis) 
than did those in the MBGrp3-HR subgroup (33 [92%] of 
36 deaths occurred within 5 years of diagnosis; 
appendix p 26).
Validation by projection of six metagenes onto an 
independent cohort8 of 276 patients (table 1) confirmed 
their existence (appendix pp 10–11). Moreover, reapplying 
consensus clustering to the combined cohort of 
704 patients confirmed a seven subgroup model as 
optimal, giving 100% concordance to the classifications 
derived separately from our discovery cohort (appendix 
pp 10–11).
Age distributions differed between the two MBSHH 
subgroups; age distributions are log-normally distributed 
and intersect at 4·3 years (figure 2A). The two peak 
incidences of age at diagnosis in infants and in older 
children for MBSHH disease,26 when observed as a whole, 
are resolved by their classification into distinct MBSHH-Infant 
and MBSHH-Child subgroups (appendix pp 12–13). Each 
MBSHH subgroup possesses characteristic molecular or 
clinicopathological features (appendix pp 12–13). LCA 
pathology (p=0·00050), MYCN amplification (p<0·0001), 
and mutations of TP53 (p<0·0001) and TERT (p=0·0015) 
were all significantly enriched in the MBSHH-Child subgroup 
compared with the MBSHH-Infant subgroup; whereas gender, 
M+ disease status, and R+ disease status were not 
significantly different between groups (figure 2B; 
appendix pp 12–13). TERT promoter mutation and 
MYCN amplification or LCA pathology were mutually 
exclusive (figure 2B; appendix pp 12–13). Mutational data 
from an independent MBSHH cohort26 showed that SUFU 
mutation was significantly associated with MBSHH-Infant, 
whereas PTCH1 mutations were observed in both MBSHH 
subgroups (figure 2C). GLI2 amplification, MYCN 
amplification, and TP53 mutations (both somatic and 
germline) were significantly associated with the MBSHH-Child 
subgroup (figure 2C).
Compared with normal cerebella and patients in the 
MBSHH-Infant subgroup, patients in the MBSHH-Child subgroup 
had subgroup-specific DNA methylation changes 
Discovery cohort 
(n=428)
Validation cohort 
(n=276)
MBSHH-Child survival 
cohort (n=55)
MBGrp3/4 survival 
cohort (n=175)
(Continued from previous page)
450K 4 subgroup assignment
MBWNT 33 (8%) 33 (12%) NA 0
MBSHH 109 (26%) 60 (22%) 24 (100%) 1 (1%)
MBGrp3 130 (31%) 72 (26%) NA 63 (36%)
MBGrp4 153 (36%) 111 (40%) NA 109 (63%)
Non-classifiable 3 NA NA 2
450K 7 subgroup assignment
MBWNT 33 (8%) 33 (12%) NA NA
MBSHH-Child 38 (9%) 32 (12%) 24 (100%) NA
MBSHH-Infant 65 (16%) 28 (10%) NA NA
MBGrp3-HighRisk 65 (16%) 51 (18%) NA 44 (25%)
MBGrp3-LowRisk 50 (12%) 20 (7%) NA 13 (7%)
MBGrp4-HighRisk 85 (21%) 54 (20%) NA 63 (36%)
MBGrp4-LowRisk 73 (18%) 58 (21%) NA 55 (31%)
Non-classifiable 19 0 NA NA
Data are n (%) or median (range), unless otherwise specified. MB=medulloblastoma. SHH=sonic hedgehog. 
Grp3=group 3. Grp4=group 4. Grp3/4=combined groups 3 and 4. NA=data not available. DN=desmoplastic or nodular. 
MBEN=medulloblastoma with extensive nodularity. LCA=large-cell anaplastic. MB-NOS=medulloblastoma not 
otherwise specified. M–=non-metastatic disease. M+=metastatic disease. RTX=radiotherapy. CTX=chemotherapy. 
WNT=wnt/wingless.
Table 1: Demographics and clinicopathological characteristics of all cohorts
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(predominantly hypermethylation), at both individual 
CpG loci and at the gene level (figure 2B; appendix 
pp 12–13), frequently involving developmental genes 
(79 [14%] of 584 genes with gene ontology term embryonic 
morphogenesis had aberrant hypermethylation). DNA 
methylation changes were validated in an independent 
cohort8 (appendix pp 12–13). When discovery cohort 
MBSHH RNA-seq expression data were available 
(190 [44%] of 428 samples), significant differential 
expression was observed between the subgroups 
(1593 genes, fold change >1·5; adjusted p<0·01; 
appendix pp 12–13). Although there were few recurrent 
cytogenetic changes, many tumours in patients in the 
MBSHH-Child subgroup (18 [51%] of 35 tumours) had loss of 
chromosome 9q, often associated with gain of 9p 
(appendix pp 12–13).
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Figure 1: Novel clinically significant subgroups within the established medulloblastoma subgroups
(A) Non-negative matrix factorisation consensus clustering of methylome data from 428 primary medulloblastomas. Each column represents one patient. Missing data are shown in grey. Residuals 
from χ² tests indicate where subgroup-enrichment has occurred (darker shades of grey indicate stronger relationships), p values are from χ² tests of enrichment; scale bar for residuals (–2 to 2) is 
shown. Methylation-derived metagene levels (V1–V6), which define subgroup membership, are also shown (red indicates high metagene levels, blue indicates low levels). (B) Overall survival of 
patients in the seven identified subgroups. All discovery cohort patients with available overall survival information are shown (n=367). (C) Progression-free survival of patients in the consensus 
four subgroups of medulloblastoma in discovery cohort patients receiving craniospinal irradiation and aged 3–16 years at diagnosis (n=250). (D) Progression-free survival of patients in the 
seven identified subgroups of medulloblastoma in patients receiving craniospinal irradiation and aged 3–16 years at diagnosis (n=239). Discrepancy in the numbers of patients in (C) and (D) is due to 
consensus clustering; certain samples could not be confidently classified for the seven subgroup model or the four subgroup model, and were omitted from the figures. DN/MBEN=desmoplastic or 
nodular medulloblastoma with extensive nodularity. HR=hazard ratio. LCA=large-cell anaplastic. M+=metastatic disease. R+=residual disease.
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The age distributions of patients in the four MBGrp3 and 
MBGrp4 subgroups differed significantly (p<0·0001). 
Patients in the MBGrp3-LR and MBGrp3-HR subgroups were 
younger at diagnosis than those in the MBGrp4-LR and 
MBGrp4-HR subgroups (appendix pp 14–15). Infants in the 
MBGrp3-HR subgroup frequently had amplified MYC (seven 
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Figure 3: Characterisation of MBGrp3 and MBGrp4 subgroups
(A) Clinicopathological and molecular disease features. Residuals from χ² tests indicate where subgroup-enrichment has occurred (darker shades of grey indicate stronger relationships); scale bar for 
residuals (–6 to 6) is shown. p values from χ² tests are shown. (B) Heat map shows the top 20 differentially methylated probes for these subgroups. Methylation data of 18 normal cerebella are shown 
alongside and magnitude of MBGrp3 and MBGrp4 metagenes is shown below. (C) Identification of MBGrp3 and MBGrp4 medulloblastoma cytogenetic determinants. Markers with p<0·05 and present in at least 
10% of one subgroup are ordered by their subgroup association and then by chromosomal order. Residuals from χ² tests indicate where subgroup enrichment has occurred (darker shades of grey 
indicate stronger relationships), across all subgroups and within MBGrp3 and MBGrp4 individually. p values from χ² tests are shown. i17q=isochromosome 17q. LCA=large-cell anaplastic. M+=metastatic 
disease. R+=residual disease.
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[64%] of 11 infants). MBGrp3-HR tumours were strongly 
associated with LCA pathology (20 [35%] of 57) and GFI1 
mutations (nine [29%] of 31; figure 3A, appendix 
pp 14–15). i17q is the sole significantly enriched feature of 
MBGrp4-HR (60 [76%] of 79 [figures 3A, 3C]. Clinico patho-
logical and molecular disease features of the MBGrp3 and 
MBGrp4 subgroups are shown in figure 3A.
Several hundred differentially methylated CpG probes 
or regions defined the four subgroups. MBGrp3-HR was 
characterised by the greatest number of significantly 
differentially methylated CpGs compared with other 
subgroups, commonly hypomethylated CpG loci 
(figure 3B; appendix pp 14–15). Notably, the low-risk 
subgroups were defined primarily by hypermethylation 
with respect to normal cerebellum, whereas the high-risk 
subgroups were defined by hypomethylation (figure 3B; 
appendix pp 14–15). Cytogenetic changes distinguished 
each subgroup as unique from the others (figure 3C). 
These distinguishing cytogenetic features were validated 
in an independent cohort (appendix pp 14–15).
We did survival analyses in an MBSHH-Child cohort that 
included 31 additional SHH cases unsuitable for 450k array 
analysis and classified as MBSHH-Child on the basis of age 
(appendix pp 4–5). In this cohort, one out of three assessable 
TP53 mutations were germline (appendix pp 16–17). TP53 
mutation was significantly associated with MYCN 
amplification (p=0·022) and LCA pathology (p=0·0033), 
MYCN amplification was associated with LCA pathology 
(p<0·0001), and LCA pathology and MYCN amplification 
were never observed with TERT mutations (p=0·00079 for 
LCA and p=0·0090 for MYCN amplification). There was no 
significant association between metastatic (M+) disease 
and TP53 mutation (p=1), MYCN amplification (p=0.15), or 
LCA pathology (p=0·67), or an association between sub-
totally resected (R+) disease and TP53 mutation (p=1), 
MYCN amplification (p=1) or LCA pathology (p=0·41). 
Univariate survival analysis of clinicobiological features 
(including risk features established in disease-wide 
studies16) in this cohort showed significantly shorter 
progression-free survival associated with MYCN 
amplification TP53 mutation, LCA pathology, M+ disease, 
and R+ disease, but no associations with TERT mutation 
status or sex (table 2; appendix pp 18–19). Multivariate Cox 
modelling, showed that MYCN amplification, TP53 
mutation, and M+ disease are independent risk factors for 
progression-free survival (table 2). Only the 42 samples 
with complete clinical information for the considered 
variables were included. The disease-wide risk-stratification 
scheme currently in use for the HIT-SIOP-PNET5-MB 
clinical trial,16 which deems MYCN amplification, LCA 
pathology, M+ disease, and R+ disease as high-risk factors, 
outperformed the MBSHH-Child subgroup stratification in AUC 
analysis (appendix pp 16–17). We used this 
HIT-SIOP-PNET5-MB stratification scheme as the basis of 
a combined risk-stratification model for MBSHH-Child 
(appendix pp 16–17), classifying patients with any one of 
these risk factors as very high risk. 50 patients had sufficient 
clinical data for classification using the scheme. This model 
discriminates favourable (24 [48%] of 50 patients, 5-year 
progression-free survival: 96% [95% CI 88–100]) and very 
high-risk (26 (52%), 5-year progression-free survival: 
29% [14–58]) groups of patients within the MBSHH-Child 
subgroup (p<0·0001; appendix pp 16–17).
Combining all craniospinally irradiated patients in the 
MBGrp3/4 subgroup aged 3–16 years who had outcome data 
(n=175), allocation to the MBGrp3-HR and MBGrp4-HR subgroups 
was a significant high-risk factor for shorter progression-
free survival in univariate analysis (table 3). Additionally, 
in multivariate analysis, MYC amplification was 
identified as an independently prognostic high-risk 
factor, and chromosome 13 loss was associated with an 
improved outcome (table 3).
n Univariate (n=55) Cross-validated 
multivariate (n=42)
HR (95% CI) p value HR (95% CI) p value
MYCN amplification vs no amplification 52 4·47 (1·65–12·1) 0·0032 2·83 (0·87–9·22) 0·084
M+ vs M– disease 55 5·69 (2·01–16·0) 0·0011 4·59 (1·28–16·4) 0·019
TP53 mutation vs no mutation 48 3·47 (1·29–9·30) 0·014 3·44 (1·15–10·2) 0·027
LCA pathology vs non-LCA pathology 52 2·88 (1·15–7·24) 0·025 ·· ··
TERT wild-type vs TERT mutation 52 2·21 (0·78–6·25) 0·13 ·· ··
R+ vs R– disease 55 3·45 (1·30–9·19) 0·013 ·· ··
Male vs female 55 1·13 (0·45–2·82) 0·79 ·· ··
p values are from Cox proportional hazards analyses. The prognostic significance of covariates selected in 
cross-validated multivariate models are also shown. HR=hazard ratio. M+=metastatic disease. M–=non-metastatic 
disease. LCA=large-cell anaplastic. R+=residual disease (subtotal surgical resection). R–=no residual disease (gross total 
resection).
Table 2: Identification of prognostic survival markers in MBSHH-Child cohort
n Univariate (n=175) Cross-validated 
multivariate (n=133)
HR (95% CI) p value HR (95% CI) p value
High-risk methylation group vs 
low-risk methylation group
175 3·73 (1·94–7·18) <0·0001 3·21 (1·59–6·51) 0·0012
MYC amplification vs no amplification 173 2·94 (1·06–8·13) 0·038 18·4 (5·01–67·7) <0·0001
Loss of chromosome 13 vs no loss 158 0·10 (0·01–0·74) 0·024 0·06 (0·01–0·49) 0·0090
MBGrp3 vs MBGrp4 175 2·04 (1·23–3·40) 0·006 ·· ··
M+ vs M– disease 171 1·77 (1·03–3·05) 0·039 ·· ··
i17q vs no i17q 158 1·71 (0·99–2·95) 0·056 ·· ··
Male vs female 175 1·56 (0·86–2·84) 0·144 ·· ··
MYCN amplification vs no 
amplification
173 0·72 (0·23–2·29) 0·576 ·· ··
LCA pathology vs non-LCA pathology 157 1·08 (0·49–2·39) 0·848 ·· ··
R+ vs R– disease 171 1·22 (0·72–2·09) 0·464 ·· ··
Identification of prognostic survival markers in combined childhood non-MBSHH and non-MBWNT survival cohort 
(aged 3·0–16·0 years, receiving craniospinal irradiation, with survival information). p values from Cox proportional 
hazards analyses are shown. The characteristics of covariates selected in cross-validated multivariate models are also 
shown. The high-risk methylomic group comprised samples from both MBGrp3 and MBGrp4, defined by the shared MBGrp3/4 
metagene V1. HR=hazard ratio. MB=medulloblastoma. Grp3=group 3. Grp4=group 4. M+=metastatic disease. 
M–=non-metastatic disease. i17q=isochromosome 17q. LCA=large-cell anaplastic. R+=residual disease (subtotal 
surgical resection). R–=no residual disease (gross total resection).
Table 3: Identification of prognostic survival markers in MBGrp3 and MBGrp4 cohorts
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A stratification model was developed that divided 
MBGrp3/4 into different risk groups for 5-year progression-
free survival: favourable risk (chromosome 13 loss and 
no MYC amplification; 16 [10%] of 153 patients; 92% 
[95% CI 79–100]); standard risk (MBGrp4-LR or MBGrp3-LR with 
no MYC amplification; 50 [33%] patients; 81% [70–94]); 
high risk (MBGrp4-HR or MBGrp3-HR with no MYC amplification; 
82 [54%] patients; 42% [31–56]); and very high risk (MBGrp3 
with MYC amplification; five [3%] patients; 0%; figure 4A; 
appendix pp 20–21). 156 patients had information for 
chromosome 13 loss and MYC amplification, of which 
three were classed as unassignable because they were 
MBGrp4 with MYC amplification (appendix pp 20–21). This 
stratification scheme outperformed current risk-
stratification models (figure 4B).
For comparison, we developed equivalent separate 
survival stratification schemes for MBGrp3 and MBGrp4 
(appendix pp 22–23). Risk factors identified were broadly 
consistent with the factors identified in the combined 
scheme, although the combined scheme was a better 
predictor of progression-free survival than when MBGrp3 
and MBGrp4 were considered separately (figure 4B). Taking 
MBGrp4 patients in isolation, in univariate analysis, a 
designation of MBGrp4-HR, chromosome 7q status, M+ 
disease, and male sex were associated with poor 
progression-free survival, whereas MYCN amplification, 
R+ disease, and LCA pathology were not (appendix 
pp 22–23). Chromosome 7q gain and M+ disease were 
retained as independent prognostic factors in multi-
variate analysis (appendix pp 22–23). A 5-year 
progression-free survival model incorporating chromo-
some 7q gain and M+ disease defined standard-risk 
(35 [32%] of 110 patients; 87% [95% CI 76–100]) and high-
risk groups (75 [68]; 49% [37–66]), and outperformed 
other published models by AUC analysis (appendix 
pp 22–23).
Taking patients with MBGrp3 in isolation, MYC 
amplification was the only risk factor significantly 
associated with progression-free survival in multivariate 
analysis, and outcomes were poor for these very high-risk 
patients (appendix pp 22–23). Patients in the MBGrp3 with 
non-MYC amplified tumours were at high risk, with 
progression-free survival similar to that for the MBGrp4-HR 
subgroup (51 [91%] of 56 patients; 46% [95% CI 33–64] 
for MBGrp3 with non-MYC amplified tumours vs 41% 
[28–60] for MBGrp4-HR). MBGrp3-HR shows a worse outcome 
than MBGrp3-LR (p=0·040; appendix p 22). LCA pathology 
(11 [21%] of 53 patients), M+ disease (17 [29%] of 
58 patients), and R+ disease (13 [22%] of 59 patients),1 
were frequent in patients in MBGrp3 but none were 
associated with prognosis, and no stratification scheme 
based on MBGrp3 alone markedly improved outcome 
prediction compared with standard stratification 
schemes (appendix pp 22–23).
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Figure 4: Novel risk stratification scheme for MBGrp3 and MBGrp4 medulloblastoma
(A) Progression-free survival plots for identified risk subgroups (n=156) defined in table 3 and the appendix (p 20). (B) Time-dependent ROC curves at 5 years are 
shown for this novel risk stratification alongside a published cytogenetic stratification scheme28 (MBGrp4 with chromosome 11 loss or chromosome 17 gain, low risk; 
MBGrp4 with M– disease, standard risk; MBGrp4 with M+ disease, high risk; MBGrp3 with MYC amplification, i17q, or M+ disease, high risk; MBGrp3 without MYC amplification, 
i17q, or M+ disease, standard risk), and the PNET5 risk stratification (patients positive for one or more of LCA pathology, M+ disease, R+ disease, MYC(N) amplification 
are high risk; patients absent for all high-risk features, standard risk), as well as the stratification derived from considering MBGrp3 and MBGrp4 as separate entities 
(appendix p 22). AUC=area under curve. LCA=large-cell anaplastic. M+=metastatic disease. M–=non-metastatic disease. ROC=receiver operating characteristic.
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The clinicopathological and molecular features of the 
new seven clinically significant subgroups are 
summarised in figure 5. The combination of subgroup-
specific survival models creates an overarching 
risk stratification for all childhood medulloblastoma 
(figure 6A). Patients are stratified into four clinical risk 
groups for 5-year progression-free survival: favourable 
risk (comprising MBWNT, MBSHH-Child with no high-risk 
features, and non-MYC amplified MBGrp3/Grp4 with 
chromosome 13 loss; 54 [25%] of 215 patients; 91% 
[95% CI 82–100]); standard risk (comprising non-MYC 
amplified MBGrp3-LR/Grp4-LR subgroups; 50 [23%] patients; 
81% [70–94]); high-risk (comprising non-MYC amplified 
MBGrp3-HR/Grp4-HR subgroups; 82 [38%] patients; 42% [31–56]); 
and very high-risk (comprising MBSHH-Child with high-risk 
features and MYC-amplified MBGrp3; 29 [13%] patients; 
28% [14–56]; figure 6B). 215 patients aged 3–16 years at 
diagnosis had data available for these factors. The AUC 
from our proposed stratification of childhood 
medulloblastoma outperforms current and proposed 
cytogenetic risk stratifications (figure 6C).28 We note that 
M+ disease status is a strong risk factor for poor 
progression-free survival in MBGrp4. Incorporation of M+ 
disease status into MBGrp4-LR and non-MYC amplified 
MBGrp3-LR survival modelling does not affect model 
performance, but potentially allows redistribution of 
standard-risk patients to create larger favourable 
(90 [41%] of 218 patients) and high-risk groups (99 [45%] 
of 218 patients; figure 6A, C; appendix pp 24–25), which 
could be considered as an alternative stratification 
scheme. The proposed refinement to the stratification 
enables additional cases classified as MBGrp3-LR and 
MBGrp4-LR that do not have copy number information 
(other than MYC amplification status) and are non-
metastatic to be classified as favourable.
Discussion
The discovery and validation of seven robust and 
reproducible primary molecular subgroups of childhood 
medulloblastoma in this retrospective cohort study 
represents, to our knowledge, the first clinically 
significant elaboration of the four-subgroup consensus 
Figure 5: Summary of the seven primary childhood medulloblastoma subgroups
Demographic, clinicopathological, and molecular features are summarised. *Comparisons of cytogenetic, gene expression, and DNA methylation changes are made with respect to their counterpart 
subgroup, except for MBWNT cases, which were compared with normal cerebella if data were available. For probe-level comparisons, Kyoto Encyclopedia of Genes and Genomes pathway enrichment of 
demethylated loci was investigated, after correcting for multiple probes mapping to the same gene (data summarised in appendix pp 27–31). CB=normal cerebella. CLAS=classic histological subtype. 
DN=desmoplastic nodular. LCA=large-cell anaplastic.
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established in 2012.1 While our work supports the 
stability of the four established groups, it also reveals 
significant substructures within each group with 
distinct clinicopathological and molecular features. 
Importantly, these primary subgroups emerge from 
unsupervised analysis, and are supported by 
distinguishing DNA methylation, gene expression, and 
copy-number profiles, consistent in discovery and 
validation cohorts. Notably, these subgroups were not 
identifiable in a previously published dataset, which 
included fewer samples and, specifically, fewer infant 
patients.8 Our seven subgroups reveal a biological 
overlap between MBGrp3 and MBGrp4. They share a 
biological signature, defined by a common metagene, 
indicating a clinicobiological overlap, which might 
suggest a common origin.
These primary subgroups may be further subdivided 
by the presence or absence of secondary molecular 
characteristics, many of which, in turn, have subgroup-
specific clinical and prognostic significance (eg, MYC 
Figure 6: Summary of survival modelling of novel medulloblastoma subgroups
(A) Summary of a novel risk-stratification scheme for childhood medulloblastoma in a cohort of patients aged 3–16 years receiving craniospinal irradiation (n=215). 
The potential to further stratify MBGrp4-LR patients into favourable and high-risk groups by their metastatic stage is shown (dashed arrows). (B) Kaplan-Meier plot of 
childhood medulloblastoma risk stratification. (C) Performance of novel stratification scheme in comparison with time-dependent ROC curves of existing schemes 
of progression-free survival at 5 years. MBGrp3/4: MBGrp3 and MBGrp4 considered as a single entity; MBGrp3/4 plus M+: MBGrp3 and MBGrp4 considered as a single entity with 
MBGrp4-LR and non-MYC amplified MBGrp3-LR further stratified by M+ disease status; MBGrp3 and MBGrp4: MBGrp3 and MBGrp4 stratified separately; cytogenetic: cytogenetically 
defined scheme;28 PNET5: scheme employed by HIT-SIOP-PNET5-MB clinical trial. LCA=large-cell anaplastic. M+=metastatic disease. M–=non-metastatic disease. 
R+=residual disease.
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amplification in MBGrp3 or TP53 mutation, MYCN 
amplification, LCA pathology, M+ disease, and R+ 
disease in MBSHH-Child). Some of these secondary features 
have been described and assigned clinical significance in 
previous studies; in this Article, their association with 
specific novel subgroups (eg, chromosome 11 loss and 
chromosome 17 gain in MBGrp4-LR28) has revealed the 
underlying biological basis of these subgroup-specific 
biomarkers. Moreover, re-evaluation of currently used 
high-risk factors derived from cohort-wide studies that 
did not consider subgroup shows that their importance 
is either low (eg, LCA pathology, M+ disease, or 
R+ disease in MBGrp3; MYCN in MBGrp4) or high (MYCN 
amplification, LCA pathology, TP53 mutation, and 
M+ disease in MBSHH-Child; MYC in MBGrp3; M+ in MBGrp4) 
when considered in the context of our new subgroups. 
Finally, the biological definition of MBSHH-Infant (<4·3 years) 
is at odds with current clinical definitions of infant 
disease (<3 years) and this should prompt consideration 
in the future as to whether infant treatment protocols are 
appropriate for MBSHH-Infant patients older than 3 years.16 
Survival modelling in children younger than 3 years is 
qualitatively different from analysis in those over 3 years 
of age, because of the heterogeneity of treatment of 
infant disease. As such, we regarded further risk 
modelling in this patient group to be outside the scope of 
this study, to be addressed in future investigations. 
To our knowledge, no previous study has directly 
assessed survival of the molecularly-defined MBSHH-Infant 
subgroup. The overall survival at 5 years that we observed 
in MBSHH-Infant disease (62%, 95% CI 50–77) is lower than 
previously reported in an international meta-analysis of 
the MBSHH subgroup in age-defined infants (<4 years at 
diagnosis; 77%),30 but these patients were not molecularly 
defined and, as such, are not directly comparable.
Our survival analysis focused on the 3–16-year-old 
clinical group who received current conventional 
therapies: surgical resection followed by adjuvant 
radiotherapy with or without chemotherapy at diagnosis 
with curative intent. Combined risk-modelling across all 
patients in the non-MBWNT or non-MBSHH subgroups 
identified MYC amplification, high-risk methylation 
subgroup membership, and loss of chromosome 13 as 
independent risk factors. Survival models incorporating 
these factors outperformed the clinical risk-stratification 
used in current clinical trials (HIT-SIOP-PNET5-MB16) 
and subgroup-dependent cytogenetic stratification 
schemes.28
We have defined a risk-stratification of childhood 
medulloblastoma that allows patients to be assigned into 
four overarching risk groups. Favourable-risk patients, 
including both MBWNT and novel non-MBWNT groups, 
should be urgently considered for therapy-reducing 
strategies. Very high-risk patients, typically refractory to 
conventional therapies (eg, amplified MYCN, mutated 
TP53, LCA pathology, and M+ disease in MBSHH and 
amplified MYC in MBGrp3) should be prioritised for 
alternative upfront treatment strategies. The priority for 
high-risk patients, comprising the novel MBGrp4-HR and 
patients with non-amplified MYC in the MBGrp3-HR 
subgroup, and a standard-risk group, comprising all 
other patients, should be optimisation of current 
therapies and the application of novel, biologically 
targeted agents.
We note the limitations of developing survival models 
in retrospective patient cohorts, who received 
heterogeneous treatments. Notwithstanding that 
models were developed using patients aged 3–16 years, 
who all received maximal surgical resection and 
craniospinal irradiation with curative intent, caution 
should be applied to their clinical implementation. We 
also note the statistical limitations of stratifications 
identifying small numbers of patients (eg, very high-
risk, 13% of patients). Moreover, some of the identified 
biomarkers (notably loss of chromosome 13) have not 
previously been reported as prognostic. We therefore 
emphasise that validation in additional cohorts, and 
ideally in prospective, uniformly treated patients in 
clinical trials, is essential. A small number of samples 
(<5 samples) from this study were used to assist with 
the creation of the four-subgroup classification 
consensus.5 Similarly, our own publication that 
described four methylation-dependent subgroups of 
medulloblastoma7 contained 87 samples that overlapped 
with this study, although the previously published study 
contained fewer samples (discovery cohort size of 100 
and validation cohort size of 130 patients) and DNA 
methylation profiling was at much lower resolution 
(1505 vs >400 000 CpG loci).
The existence of novel primary medulloblastoma 
subgroups, coupled with the characterisation of 
secondary prognostic features within each group, 
represents a significant advance in our understanding of 
medulloblastoma biology and its application in clinical 
management and future trials design. We provide clear 
evidence of the shared biology between MBGrp3 and MBGrp4, 
which affects clinical behaviour and has significant 
implications for understanding disease biology, 
developmental origins, and experimental modelling. 
These investigations constitute a blueprint for a 
new consensus in medulloblastoma molecular sub-
classification with important implications for future 
molecular diagnostics and clinical management.
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